DSIP
UnregulatedAlso known as: Delta Sleep-Inducing Peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu
Sleep & RecoveryLast reviewed: April 28, 2026
A naturally occurring nonapeptide first isolated from rabbit brain in 1977. Studied for its role in sleep regulation, stress response, and pain modulation. Popular in the biohacking community for sleep optimization.
Mechanism of Action
Modulates sleep architecture by influencing GABA, serotonin, and glutamate signaling. Promotes slow-wave (delta) sleep without suppressing REM. Also appears to modulate cortisol and ACTH, potentially reducing stress-related sleep disruption.
Common Uses
- Sleep quality improvement
- Stress reduction
- Pain modulation
- Recovery optimization
- Circadian rhythm regulation
Known Risks
- Limited human clinical data
- Short half-life (minutes) limits practical use
- Injection site reactions
- May cause morning grogginess at higher doses
- Long-term safety unknown
Regulatory Status
No FDA regulatory category. Available only as a research chemical. Not approved for any clinical indication in the US.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
100–300 mcg
Frequency
Once daily before bed
Cycle Length
2–4 weeks on, 2 weeks off
Very short half-life. Inject 30 minutes before sleep. Often stacked with Epitalon for combined sleep/longevity protocol.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.